Neoadjuvant chemotherapy followed by fast-track cytoreductive surgery plus short-course hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: preliminary results of a promising all-in-one approach

• DOI: 10.2147/cmar.s153327
• Publication Date: 2017-12-12T17:22:37Z
• Authors: Thales Paulo Batista; Vandré Carneiro; Rodrigo Tancredi; Ana Ligia Teles; Levon Badiglian-F...; Cristiano Leão
• Keywords: Hyperthermic Intraperitoneal Chemotherapy; Interim analysis; Fast track

Hyperthermic intraperitoneal chemotherapy (HIPEC) has been considered a promising treatment option for advanced or recurrent ovarian cancer, but there is no clear evidence based on randomized controlled trials to advocate this approach as standard therapy. In study, we aim present the early outcomes and insights after an interim analysis of pioneering clinical trial in Brazil.This study was cross-sectional data from our ongoing - open-label, double-center, single-arm safety efficacy using HIPEC cancer (ClinicalTrials.gov: NCT02249013). A fast-track recovery strategy also applied improve patient outcomes.Nine patients with stage IIIB (n=1) IIIC (n=8) epithelial malignancies were enrolled until February 2017. The median (range) serum CA125 level at diagnosis 692 (223.7-6550) U/mL. number preoperative cycles intravenous (i.v.) 3 (2-4), resulting peritoneal index scores 9 (3-18) time HIPEC. Time restarting i.v. 37 (33-50) days all completing 6 planned. operation 395 (235-760) minutes, length hospital stay 4 (3-10) days, left ICU morning procedure. Two experienced postoperative complications, whereas 91% complications minor G1/G2 events. Preliminary assessment suggested impairment patient's quality life.Our comprehensive protocol might represent all-in-one cancer. recruitment ongoing.